Pipeline
Optimization
CAV-011
CAV-011 targets multiple rare corneal diseases (NK, LSCD, PCED), each a vision-threatening, multibillion dollar opportunity with either no or inadequate therapeutic options.
Snapshot:
How It Works: CAV-011 is an IGF-1 variant engineered to avoid inhibition by IGF-1 binding proteins. CAV-011 drives regeneration of multiple corneal tissues, e.g., corneal nerves, corneal epithelium, and limbal cells.
Delivery: Eye drop
Indications: Neurotrophic Keratitis (NK), Limbal Stem Cell Deficiency (LSCD), and Persistent Corneal Epithelial Defect (PCED)
CAV-011 regenerating corneal nerves
Left: Vehicle-treated eye, ten days after corneal ablation
Right: CAV-011-treated eye, ten days after corneal ablation
CAV-033
CAV-033 is an Antibody-Biologic Conjugate (ABC) that directs IGF-1 to skeletal muscle. This targeted therapy increases muscle mass and strength, improves glucose metabolism, and reduces fat.
Snapshot:
How It Works: CAV-033 is an Antibody-Biologic Conjugate engineered to accumulate on the surface of muscle fibers. Once bound, CAV-033 drives muscle-specific IGF-1 receptor activation, increasing muscle size and strength.
CAV-033 in Action: A 14-day treatment with CAV-033 in mice increases muscle mass by ~30% and reduces abdominal fat by ~25%.
Indications: Rare neuromuscular disorders (e.g., DMD, FSHD, ALS), obesity, GLP-1-induced muscle loss, sarcopenia.
A single course of CAV-033 in mice increased muscle mass by 30% in 14 days.
A single course of CAV-033 in mice reduced abdominal fat by 25% in 14 days.
Meet the Team
